King's College London

PIT is a safe approach to immunoregulation in T1D with PI C19-A3 having unique properties which may be the key to switching immune attack to tolerance. In HLA DR4 positive individuals, PI C19-A3 PIT may form part of the strategy to enhance regulatory mechanisms, although full arrest of the autoimmune attack in T1D may hinge upon optimizing timing, dosing and potentially amplifying response with additional peptides. The MonoPepT1De trial aims to further establish the safety profile of this treatment and elucidate on some of these issues.